X0306 4 2016-01-19 0 0001411158 Anacor Pharmaceuticals, Inc. ANAC 0001430426 IPPOLITO VINCENT P C/O ANACOR PHARMACEUTICALS, INC. 1020 EAST MEADOW CIRCLE PALO ALTO CA 94303 0 1 0 0 EVP & Chief Commercial Officer Common Stock 2016-01-19 4 M 0 20000 19.96 A 90985 D Common Stock 2016-01-19 4 S 0 1200 93.9204 D 89785 D Common Stock 2016-01-19 4 S 0 13300 95.2867 D 76485 D Common Stock 2016-01-19 4 S 0 5300 95.9994 D 71185 D Common Stock 2016-01-19 4 S 0 200 96.95 D 70985 D Stock Option (right to buy) 19.96 2016-01-19 4 M 0 20000 0.00 D 2024-03-06 Common Stock 20000 61000 D This sale was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $93.68 to $94.575, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4) and (5) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.72 to $95.63, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $95.78 to $96.74, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $96.84 to $97.06, inclusive. The award is subject to a four-year vesting period, with 25% of the shares subject to the award vesting in an initial annual installment following the Vesting Commencement Date and 1/48th of the shares subject to the award vesting each month thereafter. The Vesting Commencement Date was February 28, 2014. /s/ Lucy O. Day, Attorney-in-fact 2016-01-21